Astellas Pharma Inc (ALPMY) 14.8000 $ALPMY Astellas'

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMY) 14.8000 $ALPMY

Astellas' Myrbetriq for Overactive Bladder Efficient as Add-On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 1:25PM CDT
Astellas Pharma Inc. (ALPMY) announced positive results from a phase IIIb study on Myrbetriq-VESIcare add-on therapy in incontinent overactive bladder patients.
ACT: 295.76 (-0.84), VRX: 225.43 (+0.80)

Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
BioPat Research - at Seeking Alpha - Tue May 12, 10:59AM CDT

MDVN: 125.90 (+3.00), JNJ: 103.42 (+1.12)

Vical Q1 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 11, 1:24PM CDT
Vical Incorporated (VICL) posted a narrower-than-expected loss of 4 cents per share in the first quarter of 2015 driven by a year-over-year surge in revenues.
VICL: 0.92 (-0.01), ILMN: 200.76 (+1.69), HSP: 88.25 (+0.15)

Medivation (MDVN) Misses on Q1 Earnings, Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 08, 2:00PM CDT
Medivation's (MDVN) first quarter results were disappointing with the company missing on both the top and the bottom-lines.
MDVN: 125.90 (+3.00), GILD: 111.00 (+1.70), OSIR: 17.78 (+0.49)

Astellas and Potenza Therapeutics team up in cancer R&D
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:54AM CDT


Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:22PM CDT
Roche Holding Ag (RHHBY) announced that its member company, Ventana Medical Systems, Inc. has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. (ALPMY).
MNK: 127.23 (+3.40), VRX: 225.43 (+0.80)

Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:30AM CDT
Merck KGaA (MKGAF) and Pfizer will have signed an agreement to co-promote Xalkori in the U.S., Canada, five countries in the EU, Japan, China and Turkey for lung cancer.
CYTK: 6.26 (+0.30), PFE: 33.98 (-0.01)

Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 3:26PM CDT
Astellas Pharma Inc. (ALPMY) and Medivation announced positive top-line results from the phase II STRIVE study comparing Xtandi to Casodex in CRPC patients.
CYTK: 6.26 (+0.30), MDVN: 125.90 (+3.00), LCI: 54.86 (+2.26)

Xtandi successful in second Phase 2 prostate cancer study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 7:56AM CDT

MDVN: 125.90 (+3.00)

Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 3:17PM CDT
Vical (VICL) expanded its infectious disease portfolio by acquiring Astellas' (ALPMY) antifungal candidate, ASP2397.
LCI: 54.86 (+2.26), VICL: 0.92 (-0.01), CBM: 40.70 (+1.70)

Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 2:20PM CDT
Medivation, Inc. (MDVN) and Astellas Pharma jointly announced new data from a randomized, double-blind phase II study (TERRAIN) on Xtandi.
CYTK: 6.26 (+0.30), MDVN: 125.90 (+3.00), AZN: 68.74 (-0.55)

Xtandi beats bicalutamide in Phase 2 CRPC trial
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:28AM CDT

MDVN: 125.90 (+3.00)

Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 5:12PM CDT
Amgen (AMGN) submits regulatory application for its cholesterol-lowering candidate, Repatha, in Japan.
LCI: 54.86 (+2.26), CBM: 40.70 (+1.70), AMGN: 163.44 (+1.08)

Best One-Drug Wonder Stock for 2015
Brian Orelli, Keith Speights, and George Budwell, The Motley Fool - Motley Fool - Sun Mar 22, 6:01AM CDT
If a biotech wants to become the next drugmaker with multiple blockbusters on the market, it has to start at the bottom with a single drug. We asked our biotech experts for their top picks for companies with just a single drug on the market. Read...
MDVN: 125.90 (+3.00), OREX: 4.98 (-0.03), ISIS: 64.33 (+1.78)

Amgen JV submits regulatory application in Japan for cholesterol med
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:59AM CDT

AMGN: 163.44 (+1.08)

United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:40PM CDT
United Therapeutics' (UTHR) cancer drug Unituxin gained FDA approval plus a priority review voucher for the treatment of pediatric patients suffering from high-risk neuroblastoma.
LCI: 54.86 (+2.26), UTHR: 179.30 (+6.55), SLXP: 172.96 (+0.15)

Astellas' Cresemba Gains FDA Approval, Under Review in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 3:44PM CDT
Astellas Pharma, Inc.'s (ALPMY) Cresemba gained FDA approval for invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
LCI: 54.86 (+2.26), ECYT: 6.15 (+0.13), SLXP: 172.96 (+0.15)

Ironwood Commences Dosing in Phase I Study on IW-1973 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 4:55PM CST
Ironwood (IRWD) initiates phase I study of its soluble guanylate cyclase (sGC) stimulator, IW-1973.
LCI: 54.86 (+2.26), ACT: 295.76 (-0.84), IRWD: 14.30 (+0.02)

FDA clears Astellas antifungal drug
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 1:46PM CST


Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 9:20AM CST
Medivation (MDVN) beats on both fourth quarter 2014 earnings and revenues; Xtandi sales rise.
MDVN: 125.90 (+3.00), BMRN: 126.02 (+3.24), CBM: 40.70 (+1.70)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 129

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kearney's 2025 Global Cities Report Insights

Updated Category News Views 654

Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...

Continue Reading
Vacca Family Law Group Enhances Support for Peaceful Divorce

Updated Category News Views 255

Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...

Continue Reading
Ingredion Delivers Impressive Q3 Results, Upgrades Outlook

Updated Category News Views 55

Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...

Continue Reading
Insight into Learning Technologies Group Plc's Disclosure Mechanism

Updated Category News Views 193

Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...

Continue Reading
Avidity Biosciences Set to Inspire with Latest Presentations

Updated Category News Views 191

Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...

Continue Reading